CTX — Crescita Therapeutics Balance Sheet
0.000.00%
- CA$11.02m
- CA$2.58m
- CA$19.58m
- 67
- 76
- 49
- 69
Annual balance sheet for Crescita Therapeutics, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 14.3 | 11.3 | 8.24 | 9.38 | 9.27 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1.36 | 3.75 | 6.24 | 2.77 | 1.72 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 19.4 | 20.1 | 20.5 | 18.5 | 15.3 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.786 | 2.58 | 2.31 | 1.85 | 2.42 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 26.8 | 28.9 | 28.5 | 24.6 | 21.8 |
Payable / Accrued | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4.62 | 6.72 | 6.06 | 4.86 | 5.51 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 5.7 | 8.4 | 7.39 | 5.78 | 5.95 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 21.1 | 20.5 | 21.1 | 18.8 | 15.8 |
Total Liabilities & Shareholders' Equity | 26.8 | 28.9 | 28.5 | 24.6 | 21.8 |
Total Common Shares Outstanding |